Ovid Therapeutics Inc (NASDAQ: OVID) on Tuesday, plunged -7.28% from the previous trading day, before settling in for the closing price of $0.4. Within the past 52 weeks, OVID’s price has moved between $0.24 and $1.47.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has jumped its sales by 24.72% annually for the last half of the decade. The company achieved an average annual earnings per share of -67.46%. With a float of $59.51 million, this company’s outstanding shares have now reached $71.11 million.
In an organization with 23 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 72.99%, operating margin of -10404.2%, and the pretax margin is -4557.12%.
Ovid Therapeutics Inc (OVID) Insider Updates
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Ovid Therapeutics Inc is 16.32%, while institutional ownership is 47.81%. The most recent insider transaction that took place on Feb 26 ’25, was worth 2,956. In this transaction President and COO of this company sold 5,279 shares at a rate of $0.56, taking the stock ownership to the 73,406 shares. Before that another transaction happened on Feb 26 ’25, when Company’s CBFO sold 3,902 for $0.56, making the entire transaction worth $2,185. This insider now owns 67,973 shares in total.
Ovid Therapeutics Inc (OVID) Performance Highlights and Predictions
According to the Wall Street analysts, stocks earnings will be around -67.46% per share during the next fiscal year.
Ovid Therapeutics Inc (NASDAQ: OVID) Trading Performance Indicators
Ovid Therapeutics Inc (OVID) is currently performing well based on its current performance indicators. A quick ratio of 4.93 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 47.57.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.35, a number that is poised to hit -0.16 in the next quarter and is forecasted to reach -0.65 in one year’s time.
Technical Analysis of Ovid Therapeutics Inc (OVID)
Let’s dig in a bit further. During the last 5-days, its volume was 0.82 million. That was better than the volume of 0.66 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 52.65%.
During the past 100 days, Ovid Therapeutics Inc’s (OVID) raw stochastic average was set at 29.62%, which indicates a significant decrease from 46.26% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.0366 in the past 14 days, which was higher than the 0.0361 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $0.3172, while its 200-day Moving Average is $0.6780. However, in the short run, Ovid Therapeutics Inc’s stock first resistance to watch stands at $0.3986. Second resistance stands at $0.4293. The third major resistance level sits at $0.4485. If the price goes on to break the first support level at $0.3487, it is likely to go to the next support level at $0.3295. Assuming the price breaks the second support level, the third support level stands at $0.2988.
Ovid Therapeutics Inc (NASDAQ: OVID) Key Stats
Market capitalization of the company is 26.17 million based on 71,110K outstanding shares. Right now, sales total 570 K and income totals -26,430 K. The company made 130 K in profit during its latest quarter, and -10,240 K in sales during its previous quarter.
